 | | Anno II – Numero 12 | Comitato scientifico editoriale: Saverio Cinieri, Umberto Malapelle
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini | | |
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial
Importance: Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM for DCIS are lacking. Objective: To compare PROs at baseline and over time in patients with low-risk DCIS randomized to receive either AM or GCC. … Continua a leggere
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
Although metastatic disease is the leading cause of cancer-related deaths, its tumor microenvironment remains poorly characterized due to technical and biospecimen limitations. In this study, we assembled a multi-modal spatial and cellular map of 67 tumor biopsies from 60 patients with metastatic breast cancer across diverse clinicopathological features and nine anatomic sites with detailed clinical annotations … Continua a leggere
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in ESR1-mutant breast cancer. This phase Ia/b trial determined the recommended phase II dose (RP2D), safety, pharmacokinetics, and efficacy of imlunestrant, as monotherapy and in combination with targeted therapy, in ER-positive (ER+) … Continua a leggere
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
Background: Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these “cold tumors”. In clinical practice, when tTMB is not available, blood-based TMB score (bTMB) can be used to consider treatment with ICIs. Methods .. Continua a leggere
Liquid biopsy biomarkers in breast cancer: An overview of systematic reviews
Breast cancer (BC) is the leading type of cancer affecting women globally and remains a significant cause of death. The diagnostic accuracy of liquid biopsy (LB) in the diagnosis of BC has not been well established. This overview synthesizes and critically evaluates the diagnostic test accuracy (DTA) of LB biomarkers in individuals with BC. Of 433 systematic reviews, eleven were included, assessing Fourier transform infrared (FTIR) spectroscopy … Continua a leggere
|
ITALIANI A SAN ANTONIO 2024
I mercoledì dell’oncologia
Webinar NON ECM, 18 dicembre dalle 17.00 alle 18.15
NSCLC AVANZATO: STRATEGIE DI IMMUNOTERAPIA
Napoli, 18 dicembre 2024
Presentazione del volume “I numeri del cancro in Italia 2024”
Roma, 19 dicembre 2024
4° BACK FROM SAN ANTONIO BREAST CANCER SYMPOSIUM
Monza, 19 dicembre 2024
Back from San Antonio
Genova, 10 – 11 gennaio 2025
Breast Cancer: Challenges and Advances in Supportive Care
I mercoledì dell’oncologia
Webinar NON ECM, 8 gennaio 2025 dalle 17.00 alle 18.15
Real world data and shared decision making: Navigating the intersection of quality, cost and survival
FAD, 13 gennaio 2025
Approccio Multidisciplinare al Tumore della Prostata
Acquaviva Delle Fonti (Ba), 14-15 Gennaio
GIST AVANZATI: IL VALORE DELLA GESTIONE MULTIDISCIPLINARE DEL PAZIENTE
Verona, 15 gennaio 2025
Breaking News sulle Terapie di Supporto in Oncologia
I mercoledì dell’oncologia
Webinar NON ECM, 22 gennaio 2025 dalle 17.00 alle 18.15
BREAKING NEWS IN BREAST CANCER
Convegno regionale AIOM Lazio
Roma, 27 gennaio 2025
XXII Conferenza Nazionale AIOM
STUDI DI FASE I
Torino, 28 febbraio – 1° marzo 2025
CORSO DI RICERCA CLINICA ASCO-AIOM (ICRC)
III edizione
Roma, 14 – 15 marzo 2025
| Questi e altri appuntamenti si possono consultare sul sito AIOM: www.aiom.it
|
| © 2023 Editore: Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – 388 8896214 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867
Per contattare la redazione e commentare le notizie clicca qui
Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy
“Realizzata con il supporto non condizionante di Menarini Stemline ”
|
|
|
|
|